Tavin EM Tablet (Tenofovir Disoproxil Fumarate and Emtricitabine)

Tavin EM Tablet is a combination of two antiviral medicines, such as emtricitabine and tenofovir disoproxil fumarate. It is prescribed to treat HIV (human immunodeficiency virus) infection. This medicine effectively prevents the virus from multiplying, thereby reducing the viral load in the body.

It also increases the CD4 cell count in the body so that your immune system can work better. This medicine helps to improve the life span and reduce the other complications during the infection. It can be used alone or in combination with other medicine.

HIV

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tavin EM Tablet (emtricitabine and tenofovir disoproxil fumarate) also causes some adverse impact on the body, most of which resolves without medical attention. However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Some common side effects include:
● Nausea
● Diarrhea
● Headache
● Depression
● Rash
● Dizziness
● Fatigue
● Vomiting
● Insomnia (difficulty sleeping)
● Weakness
● Abnormal dreams
● Abdominal pain
● Weight loss

The doctor determines the dosage and duration of Tavin EM (emtricitabine and tenofovir disoproxil fumarate) as per the severity of infection as well as age & overall health condition of the patients. Swallow it as a whole with water, and don't chew, crush, or break the tablet.

This tablet may be taken with or without food. In case of an overdose of this tablet, contact your doctor or any healthcare provider and seek medical attention immediately.

● Plosker, G. L. (2013). Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs, 73(3), 279-291.
● Mayer, K. H., Molina, J. M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., ... & Hare, C. B. (2020). Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet, 396(10246), 239-254.
● Dando, T. M., & Wagstaff, A. J. (2004). Emtricitabine/tenofovir disoproxil fumarate. Drugs, 64(18), 2075-2082.
● Glidden, D. V., Mulligan, K., McMahan, V., Anderson, P. L., Guanira, J., Chariyalertsak, S., ... & Grant, R. M. (2018). Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clinical Infectious Diseases, 67(3), 411-419.
● Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H. W., ... & Gane, E. (2014). Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 146(4), 980-988.